ANTIBODY-DRUG CONJUGATES
The concept of an ADC is simple: select a cancer-killing toxin and attach it to a specific antibody using a biodegradable linker. Developing an effective ADC, however, is far more challenging. It takes years of experience and expertise to select the right combination of cancer targets, toxic payloads, antibodies, and linkers to develop an effective, well-tolerated ADC.
TARGETS: Lung Cancer
Understanding the cancer target itself the first and most important step in the development of an ADC. Our scientists have deep expertise in target selection, including assessment of appropriate levels of expression on tumor versus normal tissue and rate of internalization.
PAYLOADS: BN0775
Our portfolio of payloads is rich and comprised of different types of cancer-killing agents, including DNA topoisomerase inhibitors and traditional microtubule inhibitors and our PKCδ inhibitor BN0775 , which are much more potent than traditional chemotherapy.
ANTIBODIES: CD56 and FRalpha
We have established knowledge in the development of tumor-targeting antibodies, having created CD56- and FRα-targeting antibodies.
LINKERS: BP-GEP
Built with stability and optimizing payload efficacy in mind, our engineered linkers are a hallmark of our ADC designs. Our scientists have created linkers that are stable outside cancer cells but are also able to break—or cleave —once inside cancer cells. The result is a released payload that is also able to enter and kill neighboring cancer cells.